The effect of tunicamycin on target cell susceptibility to natural killer cell cytotoxicity. 1987

M Nose, and M Gidlund, and Z Hosein, and I Axberg, and H Wigzell, and G Yogeeswaran

Several sets of data indicate the possibility that carbohydrate moieties on the target cell are important structures in natural killer (NK) cell-mediated lysis. Striking changes in the NK susceptibility of targets can be induced in several systems involving in vitro differentiation of tumour cell lines. The effect on target cells of the glycosylation inhibitor tunicamycin, which acts by blocking the dolichol-dependent asparagine-linked glycosylation pathway was investigated. Using several different tumour cell lines we can conclude that: asparagine-linked carbohydrate chains do not contribute directly to NK susceptibility, induced differentiation may or may not be linked with a change in NK susceptibility, and secondary changes caused by tunicamycin treatment may lead to alterations in the gangliosides, a finding that is positively correlated with decreased NK susceptibility.

UI MeSH Term Description Entries
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D007700 Kinetics The rate dynamics in chemical or physical systems.
D007951 Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. Granulocytic Leukemia,Leukemia, Granulocytic,Leukemia, Myelocytic,Leukemia, Myelogenous,Myelocytic Leukemia,Myelogenous Leukemia,Myeloid Leukemia,Leukemia, Monocytic, Chronic,Monocytic Leukemia, Chronic,Chronic Monocytic Leukemia,Chronic Monocytic Leukemias,Granulocytic Leukemias,Leukemia, Chronic Monocytic,Leukemias, Chronic Monocytic,Leukemias, Granulocytic,Leukemias, Myelocytic,Leukemias, Myelogenous,Leukemias, Myeloid,Monocytic Leukemias, Chronic,Myelocytic Leukemias,Myelogenous Leukemias,Myeloid Leukemias
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D005732 Gangliosides A subclass of ACIDIC GLYCOSPHINGOLIPIDS. They contain one or more sialic acid (N-ACETYLNEURAMINIC ACID) residues. Using the Svennerholm system of abbrevations, gangliosides are designated G for ganglioside, plus subscript M, D, or T for mono-, di-, or trisialo, respectively, the subscript letter being followed by a subscript arabic numeral to indicated sequence of migration in thin-layer chromatograms. (From Oxford Dictionary of Biochemistry and Molecular Biology, 1997) Ganglioside,Sialoglycosphingolipids
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

M Nose, and M Gidlund, and Z Hosein, and I Axberg, and H Wigzell, and G Yogeeswaran
May 1980, Journal of immunology (Baltimore, Md. : 1950),
M Nose, and M Gidlund, and Z Hosein, and I Axberg, and H Wigzell, and G Yogeeswaran
March 2002, Blood,
M Nose, and M Gidlund, and Z Hosein, and I Axberg, and H Wigzell, and G Yogeeswaran
September 1990, Cancer research,
M Nose, and M Gidlund, and Z Hosein, and I Axberg, and H Wigzell, and G Yogeeswaran
September 1998, Immunology letters,
M Nose, and M Gidlund, and Z Hosein, and I Axberg, and H Wigzell, and G Yogeeswaran
June 1987, Cancer research,
M Nose, and M Gidlund, and Z Hosein, and I Axberg, and H Wigzell, and G Yogeeswaran
January 2012, Evidence-based complementary and alternative medicine : eCAM,
M Nose, and M Gidlund, and Z Hosein, and I Axberg, and H Wigzell, and G Yogeeswaran
January 1987, Journal of immunology (Baltimore, Md. : 1950),
M Nose, and M Gidlund, and Z Hosein, and I Axberg, and H Wigzell, and G Yogeeswaran
May 1980, International journal of cancer,
M Nose, and M Gidlund, and Z Hosein, and I Axberg, and H Wigzell, and G Yogeeswaran
September 1989, Immunology letters,
M Nose, and M Gidlund, and Z Hosein, and I Axberg, and H Wigzell, and G Yogeeswaran
January 1983, Haematology and blood transfusion,
Copied contents to your clipboard!